---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010774"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:44:17.544261+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure acquires global rights to CDH6 ADC SIM0505; Q2 net loss $26.8M

## Summary
- Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC); NextCure holds rights ex-China.
- First US patient dosing for SIM0505 expected in Q3 2025; Phase 1 data in China showed partial response.
- LNCB74 (B7-H4 ADC) Phase 1 in cohort 4; backfill cohorts planned H2 2025.
- Cash $35.3M as of June 30, 2025; expects to fund operations into mid-2026.
- Simcere Zaiming made $2M equity investment; regained Nasdaq minimum bid price compliance.

## SEC filing metadata
- accession: 0001558370-25-010774
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/0001558370-25-010774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/nxtc-20250807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010774
- JSON: https://secwatch.observer/filing/0001558370-25-010774.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.